BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 24075716)

  • 1. Challenging sequential approach to treatment resistant depression: cost-utility analysis based on the Sequenced Treatment Alternatives to Relieve Depression (STAR(⁎)D) trial.
    Olgiati P; Bajo E; Bigelli M; Montgomery S; Serretti A;
    Eur Neuropsychopharmacol; 2013 Dec; 23(12):1739-46. PubMed ID: 24075716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
    Leelahanaj T
    J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distressing adverse events after antidepressant switch in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial: influence of adverse events during initial treatment with citalopram on development of subsequent adverse events with an alternative antidepressant.
    Katz AJ; Dusetzina SB; Farley JF; Ellis AR; Gaynes BN; Castillo WC; Stürmer T; Hansen RA
    Pharmacotherapy; 2012 Mar; 32(3):234-43. PubMed ID: 22392456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating depression after initial treatment failure: directly comparing switch and augmenting strategies in STAR*D.
    Gaynes BN; Dusetzina SB; Ellis AR; Hansen RA; Farley JF; Miller WC; Stürmer T
    J Clin Psychopharmacol; 2012 Feb; 32(1):114-9. PubMed ID: 22198447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.
    Leuchter AF; Husain MM; Cook IA; Trivedi MH; Wisniewski SR; Gilmer WS; Luther JF; Fava M; Rush AJ
    Psychol Med; 2010 Feb; 40(2):239-51. PubMed ID: 19493369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder.
    Leelahanaj T
    J Med Assoc Thai; 2010 Nov; 93 Suppl 6():S35-42. PubMed ID: 21284135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive socioeconomic and clinical profiles of antidepressant response and remission.
    Jain FA; Hunter AM; Brooks JO; Leuchter AF
    Depress Anxiety; 2013 Jul; 30(7):624-30. PubMed ID: 23288666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations in efficacy of antidepressant monotherapy.
    Rush AJ
    J Clin Psychiatry; 2007; 68 Suppl 10():8-10. PubMed ID: 17900203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.
    Olgiati P; Bajo E; Bigelli M; De Ronchi D; Serretti A
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):147-54. PubMed ID: 21911028
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.
    Serretti A; Olgiati P; Bajo E; Bigelli M; De Ronchi D
    World J Biol Psychiatry; 2011 Oct; 12(7):501-15. PubMed ID: 21595526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis.
    Simpson KN; Welch MJ; Kozel FA; Demitrack MA; Nahas Z
    Adv Ther; 2009 Mar; 26(3):346-68. PubMed ID: 19330495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and drug induced side effects in early versus late antidepressant responders.
    Fabbri C; Marsano A; Balestri M; De Ronchi D; Serretti A
    J Psychiatr Res; 2013 Oct; 47(10):1309-18. PubMed ID: 23800418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Electroconvulsive Therapy vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United States.
    Ross EL; Zivin K; Maixner DF
    JAMA Psychiatry; 2018 Jul; 75(7):713-722. PubMed ID: 29800956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
    Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
    Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic impact of nonpersistence with antidepressant treatment in the adult population of Quebec: a comparative cost-effectiveness approach.
    Béland SG; Tournier M; Galbaud du Fort G; Crott R; Ducruet T; Pariente A; Moride Y
    Value Health; 2011 Jun; 14(4):492-8. PubMed ID: 21669374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K; Hemels ME; Hudry J; Annemans L
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
    Rush AJ; Fava M; Wisniewski SR; Lavori PW; Trivedi MH; Sackeim HA; Thase ME; Nierenberg AA; Quitkin FM; Kashner TM; Kupfer DJ; Rosenbaum JF; Alpert J; Stewart JW; McGrath PJ; Biggs MM; Shores-Wilson K; Lebowitz BD; Ritz L; Niederehe G;
    Control Clin Trials; 2004 Feb; 25(1):119-42. PubMed ID: 15061154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression.
    Bosmans JE; Hermens ML; de Bruijne MC; van Hout HP; Terluin B; Bouter LM; Stalman WA; van Tulder MW
    J Affect Disord; 2008 Nov; 111(1):106-12. PubMed ID: 18342952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.
    Nakajima S; Uchida H; Suzuki T; Watanabe K; Hirano J; Yagihashi T; Takeuchi H; Abe T; Kashima H; Mimura M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1983-9. PubMed ID: 21889560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study.
    Zisook S; Lesser IM; Lebowitz B; Rush AJ; Kallenberg G; Wisniewski SR; Nierenberg AA; Fava M; Luther JF; Morris DW; Trivedi MH
    J Clin Psychiatry; 2011 Oct; 72(10):1322-32. PubMed ID: 22075098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.